![Shaharyar Khan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shaharyar Khan
Director Técnico/Científico/I+D en Rivus Pharmaceuticals, Inc. .
Cargos activos de Shaharyar Khan
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Rivus Pharmaceuticals, Inc.
![]() Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Director/Miembro de la Junta | - | - |
Director Técnico/Científico/I+D | - | - |
Historial de carrera de Shaharyar Khan
Estadísticas
Internacional
Estados Unidos | 2 |
Operativa
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Rivus Pharmaceuticals, Inc.
![]() Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Health Technology |
- Bolsa de valores
- Insiders
- Shaharyar Khan
- Experiencia